How effective is Quizartinib in myeloid leukemia?

Quizartinib (Quizartinib) is a highly selective, oral FLT3 inhibitor, mainly used to treat patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations. FLT3-ITD mutation is one of the most common gene mutations in AML and is closely related to the aggressiveness of the disease and poor prognosis.

Quizatinib exerts anti-tumor effects by inhibiting the activation ofFLT3 receptor and blocking the proliferation and survival signals of leukemia cells. In clinical trials, quizartinib showed good efficacy. For example, in a phase III clinical trial called QuANTUM-First, quizartinib combined with standard chemotherapy was used in patients with newly diagnosed FLT3-ITD-positive AML and significantly prolonged the overall survival of the patients. The results of the trial showed that the median overall survival in the quizartinib group was 31.9 months, compared with 15.1 months in the control group, indicating that quizartinib has a significant advantage in prolonging patient survival.

In addition, quizartinib has also shown certain efficacy in the treatment of relapsed or refractory AML patients. In a phase II clinical trial, a higher complete response rate and a longer duration of response were observed with quizatinib monotherapy in patients with relapsed or refractory FLT3-ITD-positive AML. These results further support the potential of quizartinib in the treatment of AML.

It should be noted that quizartinib may cause some adverse reactions, such asQT interval prolongation, arrhythmia, and bone marrow suppression. Therefore, during treatment with quizartinib, patients should undergo regular electrocardiogram monitoring and blood tests to detect and deal with possible side effects in a timely manner.

In short, quizartinib, as a therapeutic drug targetingFLT3-ITD mutation, has shown good efficacy in the treatment of acute myeloid leukemia, especially in prolonging patient survival. However, patients should closely monitor possible adverse reactions when using this drug under the guidance of a professional physician to ensure the safety and effectiveness of the treatment.

Reference materials:https://go.drugbank.com/drugs/DB12874